Why the study?
Diuretic therapy for congestion in ADHF may cause worsening renal function, but the clinical efficacy of tolvaptan add-on therapy on reducing worsening renal function has been inconsistent.
Does tolvaptan add-on therapy reduce worsening renal function in patients with acute decompensated heart failure?
Does tolvaptan add-on therapy reduce worsening renal function in patients with acute decompensated heart failure?
In patients with acute decompensated heart failure, adding tolvaptan to standard diuretic therapy does not reduce worsening renal function or short-term mortality, although it effectively decreases body weight and increases sodium levels.
Answers are grounded in this paper and cite their sources.
Tolvaptan add-on does not reduce worsening renal function in acute decompensated heart failure; confirms lack of renal benefit in meta-analysis of trials.
Objectives Treating acute decompensated heartfailure (ADHF) for improving congestion with diuretics may cause worsening renal function (WRF), but the clinical efficacy of tolvaptan add-on therapy on reducing WRF in ADHF patients is inconsistent. This analysis is to evaluate the effects of tolvaptan add-on therapy on reducing WRF in ADHF patients. Methods Meta-analysis of randomised trials of tolvaptan add-on therapy on reducing WRF in ADHF patients. The MEDLINE, Embase and Cochrane Central Register of Controlled Trials databases were searched for relevant articles from their inception to 31 October, 2017. Two reviewers filtrated the documents on WRF, short-term all-cause mortality, body weight decreased, elevated sodium level for calculating pooled relatives risks, weighted mean difference and associated 95% CIs. We used fixed-effects or random-effects models according to I 2 statistics. Achievements Seven random controlled trials with 937 patients were included for analysis. Compared with the control, tolvaptan add-on therapy did not improve incidence of worsening renal function (RR 0.78, 95% CI 0.48 to 1.26, p=0.31, I 2 =66%) and short-term all-cause mortality (RR 0.85, 95% CI 0.47 to 1.56, p=0.61, I 2 =0%). On subgroup analyses, there was a suggestion of possible effect modification by dose of tolvaptan, in which benefit was observed in low-dose (≤15 mg/day) group (RR 0.48, 95% CI 0.23 to 1.02, p=0.05, I 2 =54%), but not with high-dose (30 mg) group (RR 1.33, 95% CI 0.99 to 1.78, p=0.05, I 2 =0%). However, tolvaptan add-on therapy reduced body weight in 2 days (standardised mean difference −0.49, 95% CI −0.64 to −0.34, p<0.00001, I 2 =0%), increased sodium level (mean difference 1.56, 95% CI 0.04 to 3.07, p=0.04, I 2 =0%). Conclusion The result suggests that comparing with the standard diuretic therapy, tolvaptan add-on therapy did not reduce the incidence of WRF and short-term mortality, however, it can decrease body weight and increase the sodium level in patients who are with ADHF. Further researches are still required for confirmation.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: